Trutakna Injection, Solution
Product Images NDC 85052-101

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Trutakna (NDC 85052-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vera Therapeutics, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Trutakna 01)

Line graph showing mean change from baseline in UPCR (urine protein-to-creatinine ratio) over 36 weeks comparing placebo (dashed gray line) and Trutakna (solid blue line). Trutakna group shows a larger decrease in UPCR than placebo, with data points at weeks 0, 12, 24, and 36. Sample sizes per group per visit are listed below the x-axis.*

FDA Label Image

Figure (Trutakna 02)

Trutakna 150 mg/1 mL injection pen for subcutaneous use, containing atacicept. The pen features the product name and generic name vertically printed on a white background with a visible window showing the solution inside. The device has a blue cap at the bottom. Labeler is Vera Therapeutics, Inc.*

FDA Label Image

Figure A (Trutakna 03)

Illustration showing an overview of Trutakna (atacicept) 150 mg autoinjector parts before and after use. The diagram highlights the label with lot number and expiration date, a viewing window showing liquid medicine or filled with blue after use, a gray stopper tip, cap, and a hidden needle inside with a needle shield after use.*

FDA Label Image

Figure B (Trutakna 04)

Illustration showing a Trutakna (atacicept-vymj) injection syringe with labels pointing to the gray stopper tip, the viewing window displaying liquid medicine, and the cap. The syringe is labeled for subcutaneous injection and includes a placeholder for expiration date and lot number.*

FDA Label Image

Figure C (Trutakna 05)

An instructional diagram showing recommended subcutaneous injection sites on the body. Highlighted areas include the stomach (abdomen) except a 2-inch area around the navel, and the front and outer sides of both thighs. The figure is labeled as Figure C.*

FDA Label Image

Figure D (Trutakna 06)

An instructional illustration labeled Figure D depicting a hand holding a wipe or cloth, cleaning or preparing a patch of skin on an arm. This image is likely part of usage or administration instructions for a subcutaneous injection.*

FDA Label Image

Figure E (Trutakna 07)

An instructional illustration showing the removal of the cap from a needle shield of a subcutaneous injection device, followed by the disposal of the used needle shield into a sharps container. The image is part of the administration steps for the Trutakna (atacicept) injection.*

FDA Label Image

Figure F (Trutakna 08)

Instructional diagram showing subcutaneous injection technique for Trutakna injection, solution. A hand holds the injection device at a 90-degree angle to the skin, with direction to hold down for 15 seconds. Insets depict the device's visual indicator before, during, and after injection.*

FDA Label Image

Figure G (Trutakna 09)

Illustration showing a hand holding an injection device at a 90-degree angle to the skin surface. The image emphasizes the proper vertical positioning of the device for subcutaneous injection, indicated by an upward arrow, labeled as Figure G.*

FDA Label Image

Carton Label (Trutakna 10)

The packaging label for Trutakna (atacicept-vymi) injection, 150 mg/mL, shows a box containing four single-dose pre-filled autoinjectors for subcutaneous use. The label features the product name and strength prominently, the Vera Therapeutics logo, storage instructions, and a depiction of the autoinjector device with a blue cap. The packaging also includes NDC 85052-101-04 and indicates it is a human prescription drug.*

FDA Label Image

Autoinjector Label (Trutakna 11)

Label for Trutakna (atacicept-vymj) injection, 150 mg/mL, a subcutaneous injection solution. The label indicates it is a single-dose pre-filled autoinjector. Manufactured by Vera Therapeutics Inc., Brisbane, CA, with U.S. license #2386. The NDC is 85052-101-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.